The effects of lacosamide on cognitive function and psychiatric profiles in patients with epilepsy

• Published in: Epilepsy & behavior Vol. 113; p. 107580
• Main Authors: Li, Kuan-Ying, Huang, Ling-Chun, Chang, Yang-Pei, Yang, Yuan-Han
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.12.2020
• Subjects: Adult; Affect - drug effects; Anticonvulsants - pharmacology; Anticonvulsants - therapeutic use; Carbamazepine - pharmacology; Carbamazepine - therapeutic use; Cognition; Cognition - drug effects; Depression; Epilepsy; Epilepsy - drug therapy; Epilepsy - psychology; Humans; Lacosamide; Lacosamide - pharmacology; Lacosamide - therapeutic use; Lamotrigine - pharmacology; Lamotrigine - therapeutic use; Mood; Pyridones; Quality of Life; Topiramate - pharmacology; Topiramate - therapeutic use; Depression; Cognition; Mood; Epilepsy; Lacosamide
• ISSN: 1525-5050; 1525-5069
• DOI: 10.1016/j.yebeh.2020.107580

•Patients’ quality of life can be affected by anti-seizure medications side effects.•Lacosamide might have low risks for significant changes in cognition or mood.•Concomitant medicines and disorders play roles in developing Lacosamide side effects. Cognitive and psychiatric problems are common in people with epilepsy. They can have multiple causes, including structural brain lesions, the active epilepsy, and the effect of anti-epileptic therapy. Since patients’ treatment compliance and quality of life are affected by cognitive and emotional status, it is crucial for clinicians to understand how anti-seizure medications (ASMs) affect cognition and mood, and to choose the proper ASM. To conduct a literature review of the impact on cognition and mood status of lacosamide (LCM) in people with epilepsy. Wesearched PubMed, the Cochrane Database of Systematic Reviews and reference lists of articles for all types of articles with no limitations on publication date. A total of 251 records were obtained, including 247 articles in PubMed and 4 articles from reference lists. We included 2 meta-analyses, one randomized controlled trials and 14 observational studies after the screening process. Most studies agree LCM has low risk of treatment-emergent adverse events (TEAEs) on cognition. Comparisons with other ASMs, LCM may be preferable to carbamazepine, topiramate and perampanel, and not inferior to lamotrigine. In spite of low incident rate, depression is the most common psychiatric change of LCM. There are no consistent positive or negative psychiatric effects of LCM. Lacosamide has limited impact on cognitive and mood status in this review. Several factors including mechanism of co-administration of ASMs and personal history of psychiatric disorder should be considered as important in the development of cognitive and psychiatric side effects. However, the heterogeneity between studies make the quality of evidence weaker and further trials are needed.